Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus Added to Adjuvant Endocrine Therapy in Poor-Prognosis ER+ HER2- Breast Cancer
2012-003187-44Phase 3Active
- Sponsor
- Unicancer
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Everolimus + adjuvant hormone therapy with Placebo + adjuvant hormone therapy (2 arms). Primary endpoint: Disease-free survival rate after randomization. Started Sep 2012; status: active.
02
Drugs
everolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-003187-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003187-44.